Developing first-in-class Nck modulators for autoimmune disease

Our first-in-class, novel mechanism holds broad potential to treat T cell mediated autoimmune diseases such as psoriasis, atopic dermatitis, psoriatic arthritis, ankylosing spondylitis, and many others, while simultaneously allowing the body to fight foreign pathogens.


Psoriasis is an autoimmune disease affecting the skin. It causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp. Psoriasis is a long-term disease with no cure. It can be painful, interfere with sleep, and make it hard to concentrate. It is estimated that more than 7 million adults in the US have psoriasis today. AX-158 is an oral agent currently being tested in patients with mild to moderate psoriasis, with first results expected in Q4 2024.

Atopic dermatitis

Atopic dermatitis (atopic eczema) is a chronic, relapsing, and remitting inflammatory skin disease affecting one in 10 people in their lifetime. Repeated scratching triggers a self-perpetuating itch-scratch cycle, which can have a significant impact on the patient’s quality of life. We plan to initiate a Phase 2 clinical trial with AX-158 in patients with moderate to severe atopic dermatitis later in 2024.

Autoimmune disease

We also plan to investigate the potential efficacy and safety of AX-158 in an additional autoimmune indication.

Additional programs

We are developing additional Nck modulator candidates for autoimmune diseases. AX-194 is undergoing preclinical testing to enter Phase 1 clinical safety trials in healthy human volunteers.